Is oncogene addiction angiogenesis-dependent?

Cold Spring Harbor Symposia on Quantitative Biology

Volumn 70, Issue , 2005, Pages 389-397

  Folkman, J ^a   Ryeom, S ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; THROMBOSPONDIN; DOXYCYCLINE; THROMBOSPONDIN 1;

ADDICTION; ANGIOGENESIS; APOPTOSIS; CARDIOVASCULAR FUNCTION; CELL ACTIVITY; CELL PROLIFERATION; CONFERENCE PAPER; IN VIVO STUDY; NONHUMAN; ONCOGENE; ONCOGENE C MYC; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL; TUMOR REGRESSION; ARTICLE; GENE MUTATION; GENE OVEREXPRESSION; MOUSE; TUMOR GROWTH;

ANIMALS; APOPTOSIS; CELL PROLIFERATION; DOXYCYCLINE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, MYC; HUMANS; MICE; MICE, SCID; MICE, TRANSGENIC; MODELS, BIOLOGICAL; NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; ONCOGENES; THROMBOSPONDIN 1;

EID: 33746411429     PISSN: 00917451     EISSN: None     Source Type: Book Series    
DOI: 10.1101/sqb.2005.70.042     Document Type: Conference Paper

References (47)

1. Achilles E.G., Fernandez A., Allred E.N., Kisker O., Udagawa T., Beecken W.D., Flynn E., and Folkman J. 2001. Heterogeneity of angiogenic activity in a human liposarcoma: A proposed mechanism for "no take" of human tumors in mice. J. Natl. Cancer Inst. 93: 1075.
2. Almog N., Henke V., Flores L., Hlatky L., Kung A., Wright R.D., Berger R., Hutchinson L., Naumov G., Bender E., Akslen L., Achilles E.G., and Folkman J. 2006. Prolonged dormancy of human liposarcoma is associated with impaired tumor angiogenesis. FASEB J. (in press).
3. Arbiser J.L., Moses M.A., Fernandez C.A., Ghiso N., Cao Y., Klauber N., Frank D., Brownlee M., Flynn E., Parangi S., Byers H.R., and Folkman J. 1997. Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways. Proc. Natl. Acad. Sci. 94: 861.
4. Auerbach R., Arensman R., Kubai L., and Folkman J. 1975. Tumor-induced angiogenesis: Lack of inhibition by irradiation. Int. J. Cancer 15: 241.
5. Baudino T.A., McKay C., Pendeville-Samain H., Nilsson J.A., Maclean K.H., White E.L., Davis A.C., Ihle J.N., and Cleveland J.L. 2002. c-Myc is essential for vasculogenesis and angiogenesis during development and tumor progression. Genes Dev. 16: 2530.
6. Brandvold K.A., Neiman P., and Ruddell A. 2000. Angiogenesis is an early event in the generation of myc-induced lymphomas. Oncogene 19: 2780.
7. Browder T., Butterfield C.E., Kraling B.M., Shi B., Marshall B., O'Reilly M.S., and Folkman J. 2000. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. 60: 1878.
8. Chin L., Tam A., Pomerantz J., Wong M., Holash J., Bardeesy N., Shen Q., O'Hagan R., Pantginis J., Zhou H., Horner J.W., Cordon-Cardo C., Yancopoulos G.D., and DePinho R.A. 1999. Essential role for oncogenic Ras in tumour maintenance. Nature 400: 468.
9. Dameron K.M., Volpert O.V., Tainsky M.A., and Bouck N. 1994. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 265: 1582.
10. Eggert A., Ikegaki N., Kwiatkowski J., Zhao H., Brodeur G.M., and Himelstein B.P. 2000. High-level expression of angiogenic factors is associated with advanced tumor stage in human neuroblastomas. Clin. Cancer Res. 6: 1900.
11. Ezzell C. 1998. Starving tumors of their lifeblood. Sci. Am. 279: 33.
12. Felsher D.W. and Bishop J.M. 1999. Reversible tumorigenesis by MYC in hematopoietic lineages. Mol. Cell 4: 199.
13. Fernandez A., Udagawa T., Schwesinger C., Beecken W., Achilles-Gerte E., McDonnell T., and D'Amato R. 2001. Angiogenic potential of prostate carcinoma cells overexpressing Bcl-2. J. Natl. Cancer Inst. 93: 208.
14. Folkman J. 2000. Tumor angiogenesis. In Cancer medicine, 5th edition (ed. J.F. Holland et al.), p. 132. B.C. Decker, Hamilton, Ontario, Canada.
15. _. 2004. Endogenous angiogenesis inhibitors. Acta Pathol. Microbiol. Immunol. Scand. 112: 496.
16. _. 2006. Antiangiogenesis in cancer therapy - endostatin and its mechanisms of action. Exp. Cell Res. 312: 594.
17. Folkman J. and Kalluri R. 2004. Cancer without disease. Nature 427: 787.
18. Folkman J., Heymach J., and Kalluri R. 2006. Tumor angiogenesis. In Cancer medicine, 6th edition (ed. D.W. Kufe et al.), p. 157. B.C. Decker, Hamilton, Ontario, Canada.
19. _. 2004. Cancer without disease. Nature 427: 787.
20. Giuriato S. and Felsher D.W. 2003. How cancers escape their oncogene habit. Cell Cycle 2: 329.
21. Hanahan D. and Folkman J. 1996. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86: 353.
22. Holmgren L., O'Reilly M.S., and Folkman J. 1995. Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat. Med. 1: 149.
23. Jain M., Arvanitis C., Chu K., Dewey W., Leonhardt E., Trinh M., Sundberg C.D., Bishop J.M., and Felsher D.W. 2002. Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science 297: 102.
24. Karlsson A., Giuriato S., Tang F., Fung-Weier J., Levan G., and Felsher D.W. 2003. Genomically complex lymphomas undergo sustained tumor regression upon MYC inactivation unless they acquire novel chromosomal translocations. Blood 101: 2797.
25. Kerbel R.S. and Kamen B.A. 2004. The anti-angiogenic basis of metronomic chemotherapy. Nat. Rev. Cancer 4: 423.
26. Kim K.J., Li B., Winer J., Armanini M., Gillett N., Phillips H.S., and Ferrara N. 1993. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362: 841.
27. Klement G., Baruchel S., Rak J., Man S., Clark K., Hicklin D.J., Bohlen P., and Kerbel R. 2000. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J. Clin. Invest. 105: R15.
28. Naumov G.N., Bender E., Zurakowski D., Kang S.-Y., Sampson D., Flynn E., Watnick R.S., Straume O., Akslen L.A., Folkman J., and Almog N. 2006. A model of human tumor dormancy: An angiogenic switch from the nonangiogenic phenotype. J. Natl. Cancer Inst. 98: 316.
29. Nyberg P., Xie L., and Kalluri R. 2005. Endogenous inhibitors of angiogenesis. Cancer Res. 65: 3967.
30. O'Reilly M.S., Boehm T., Shing Y., Fukai N., Vasios G., Lane W.S., Flynn E., Birkhead J.R., Olsen B.R., and Folkman J. 1997. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell 88: 277.
31. O'Reilly M.S., Holmgren L., Shing Y., Chen C., Rosenthal R.A., Moses M., Lane W.S., Cao Y., Sage E.H., and Folkman J. 1994. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79: 315.
32. Rak J., Yu J. L., Klement G., and Kerbel R.S. 2000. Oncogenes and angiogenesis: Signaling three-dimensional tumor growth. J. Investig. Dermatol. Symp. Proc. 5: 24.
33. Ravi R., Mookerjee B., Bhujwalla Z.M., Sutter C.H., Artemov D., Zeng Q., Dillehay L.E., Madan A., Semenza G.L., and Bedi A. 2000. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. Genes Dev. 14: 34.
34. Relf M., LeJeune S., Scott P.A., Fox S., Smith K., Leek R., Moghaddam A., Whitehouse R., Bicknell R., and Harris A.L. 1997. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res. 57: 963.
35. Satchi-Fainaro R., Puder M., Davies J.W., Tran H.T., Sampson D.A., Greene A.K., Corfas G., and Folkman J. 2004. Targeting angiogenesis with a conjugate of HPMA copolymer and TNP-470. Nat. Med. 10: 255.
36. Satchi-Fainaro R., Mamluk R., Wang L., Short S.M., Nagy J.A., Feng D., Dvorak A.M., Dvorak H.F., Puder M., Mukhopadhyay D., and Folkman J. 2005. Inhibition of vessel permeability by TNP-470 and its polymer conjugate, caplostatin. Cancer Cell 7: 251.
37. Shachaf C.M., Kopelman A.M., Arvanitis C., Karlsson A., Beer S., Mandl S., Bachmann M.H., Borowsky A.D., Ruebner B., Cardiff R.D., Yang Q., Bishop J.M., Contag C.H., and Felsher D.W. 2004. MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. Nature 431: 1112.
38. Sherif Z.A., Nakai S., Pirollo K.F., Rait A., and Chang E.H. 2001. Downmodulation of bFGF-binding protein expression following restoration of p53 function. Cancer Gene Ther. 8: 771.
39. Streit M., Riccardi L., Velasco P., Brown L.F., Hawighorst T., Bornstein P., and Detmar M. 1999. Thrombospondin-2: A potent endogenous inhibitor of tumor growth and angiogenesis. Proc. Natl. Acad. Sci. 96: 14888.
40. Sudhakar A., Sugimoto H., Yang C., Lively J., Zeisberg M., and Kalluri R. 2003. Human tumstatin and human endostatin exhibit distinct antiangiogenic activities mediated by alpha v beta 3 and alpha 5 beta 1 integrins. Proc. Natl. Acad. Sci. 100: 4766.
41. Tang Y., Kim M., Carrasco D., Kung A.L., Chin L., and Weissleder R. 2005. In vivo assessment of Ras-dependent maintenance of tumor angiogenesis by real-time magnetic resonance imaging. Cancer Res. 65: 8324.
42. Udagawa T., Fernandez A., Achilles E.G., Folkman J., and D'Amato R.J. 2002. Persistence of microscopic human cancers in mice: Alterations in the angiogenic balance accompanies loss of tumor dormancy. FASEB J. 16: 1361.
43. Uehara H. 2003. Angiogenesis of prostate cancer and antiangiogenic therapy. J. Med. Invest. 50: 146.
44. Volpert O. and Alani R. M. 2003. Wiring the angiogenic switch: Ras, Myc, and Thrombospondin-1. Cancer Cell 3: 199.
45. Watnick R.S., Cheng Y.-N., Rangarajan A., Ince T.A., and Weinberg R.A. 2003. Ras modulates Myc activity to repress thrombospondin-1 expression and increase tumor angiogenesis. Cancer Cell 3: 219.
46. Weinstein I.B. 2002. Addiction to oncogenes: The Achilles heal of cancer. Science 297: 63.
47. Zhang L., Yu D., Hu M., Xiong S., Lang A., Ellis L.M., and Pollock R.E. 2000. Wild-type p53 suppresses angiogenesis in human leiomyosarcoma and synovial sarcoma by transcriptional suppression of vascular endothelial growth factor expression. Cancer Res. 60: 3655.